Working with Industry｜Networks｜Center for Cancer Immunotherapy and Immunobiology

Working with Industry
Bringing new therapies to market requires an extensive collaboration between basic science, technology development, and pre-clinical and clinical research. While our main research focus is on fundamental research, we also support extensive collaborations with industry, based on decades of experience in working with biotechnology and pharmaceutical companies at Tasuku Honjo’s lab at Kyoto University.

Overview

Estimated at 10s of billion of US$ today, the market for cancer immunotherapy drugs today is likely to grow over the next decades as enhanced treatments are becoming available to an increasing number of patients in developed and increasingly also in developing countries. Working with industry actors is crucial in the quest to enhance cancer immunotherapy. With organizations such as Ki-CONNECT, Kyoto University has build-up an infrastructure to support collaborations with the biotechnology and pharmaceutical industry. CCII’s new research building will also provide special facilities to facilitate collaboration and host scientist from industry at the center.

A New Metabolomics Platform to Enhance Cancer Therapy

Shimadzu Corporation is a leading instrument maker located in Kyoto whose pioneering work in mass spectroscopy of biological macromolecules resulted in the 2002 Nobel Prize in Chemistry for Koichi Tanaka, one of its development engineers. Working closely with scientist at Shimadzu, CCII has built a powerful metabolomics platform that can analyze hundreds of metabolites and lipids in plasma samples.